U.S. trade controls generate significant risks for unwary players in the life sciences industry.
There are challenging regulations throughout the entire life cycle of a product. Noncompliance can cause supply chain and product shipment disruptions, order cancelations, fines, or even damage corporate reputation.
Compounded with the fact that most companies in the Life Sciences sector do not operate their businesses with an enterprise-wide view of risk, due partly to globalization and the need to work within different regulatory environments- expansion into new markets brings with it more risk.
Featuring:
Tahlia Townsend, partner, International Trade Compliance at Wiggin and Dana, LLP
Dan Goren, partner, International Trade Compliance Practice Group at Wiggin and Dana, LLP
Brought to you by Cure by Deerfield
The Cure at 345 Park Avenue South, leading life science, digital health, and tech-enabled companies from across the world come together to uncover cutting-edge solutions for those in need. We provide laboratories, engineering and computing space, and other amenities and supportive services to help today’s thought leaders build a better tomorrow.